Wells Fargo & Company Cuts Cencora (NYSE:COR) Price Target to $237.00

Cencora (NYSE:COR) had its target price lowered by equities research analysts at Wells Fargo & Company from $249.00 to $237.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 2.07% from the company’s current price.

A number of other research firms also recently weighed in on COR. Evercore ISI increased their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Robert W. Baird upped their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. UBS Group upped their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Bank of America reaffirmed a “neutral” rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. upped their price target on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Trading Up 0.0 %

NYSE COR traded up $0.08 on Friday, reaching $232.20. The company had a trading volume of 190,333 shares, compared to its average volume of 1,384,406. The firm has a market cap of $44.88 billion, a price-to-earnings ratio of 30.92, a P/E/G ratio of 1.54 and a beta of 0.45. Cencora has a fifty-two week low of $195.83 and a fifty-two week high of $253.27. The business has a 50 day moving average of $238.11 and a two-hundred day moving average of $233.82. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cencora

Several institutional investors and hedge funds have recently added to or reduced their stakes in COR. Dynamic Advisor Solutions LLC increased its stake in shares of Cencora by 9.4% during the 2nd quarter. Dynamic Advisor Solutions LLC now owns 1,012 shares of the company’s stock worth $228,000 after purchasing an additional 87 shares during the last quarter. ORG Partners LLC purchased a new stake in shares of Cencora during the 2nd quarter worth approximately $81,000. Blue Trust Inc. increased its stake in shares of Cencora by 58.5% during the 2nd quarter. Blue Trust Inc. now owns 1,330 shares of the company’s stock worth $323,000 after purchasing an additional 491 shares during the last quarter. Vista Investment Partners LLC boosted its holdings in Cencora by 1.0% in the 2nd quarter. Vista Investment Partners LLC now owns 19,393 shares of the company’s stock worth $4,369,000 after buying an additional 195 shares during the period. Finally, Vaughan Nelson Investment Management L.P. boosted its holdings in Cencora by 185.5% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 131,873 shares of the company’s stock worth $29,710,000 after buying an additional 85,680 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.